TY - JOUR
T1 - Six cases of Aerococcus sanguinicola infection
T2 - Clinical relevance and bacterial identification
AU - Ibler, Kristina
AU - Truberg Jensen, Kjeld
AU - Østergaard, Christian
AU - Wolff Sönksen, Ute
AU - Bruun, Brita
AU - Schønheyder, Henrik C.
AU - Kemp, Michael
AU - Dargis, Rimtas
AU - Andresen, Keld
AU - Jørgen Christensen, Jens
PY - 2008/9/4
Y1 - 2008/9/4
N2 - Aerococcus sanguinicola is a Gram-positive coccus first described in 2001. Infections in humans are rare but the use of 16S rRNA gene sequencing and improved phenotypic methods has facilitated the identification of A. sanguinicola. We report here 6 cases of A. sanguinicola bacteraemia, 2 of which were associated with infective endocarditis. Most patients were elderly (median age 70 y) and had underlying neurological disorders including dementia, cerebral degeneration, and myelomeningocele. The primary focus of infection was the urinary tract in 3 cases and the gallbladder in 1; no focus was detected in 2 cases. Long-term prognosis was poor reflecting the frailty of the patients. All strains were susceptible to penicillin, ampicillin, cefuroxime, vancomycin, erythromycin, and rifampicin. The optimal treatment of infection with A. sanguinicola has yet to be determined.
AB - Aerococcus sanguinicola is a Gram-positive coccus first described in 2001. Infections in humans are rare but the use of 16S rRNA gene sequencing and improved phenotypic methods has facilitated the identification of A. sanguinicola. We report here 6 cases of A. sanguinicola bacteraemia, 2 of which were associated with infective endocarditis. Most patients were elderly (median age 70 y) and had underlying neurological disorders including dementia, cerebral degeneration, and myelomeningocele. The primary focus of infection was the urinary tract in 3 cases and the gallbladder in 1; no focus was detected in 2 cases. Long-term prognosis was poor reflecting the frailty of the patients. All strains were susceptible to penicillin, ampicillin, cefuroxime, vancomycin, erythromycin, and rifampicin. The optimal treatment of infection with A. sanguinicola has yet to be determined.
UR - http://www.scopus.com/inward/record.url?scp=50549087896&partnerID=8YFLogxK
U2 - 10.1080/00365540802078059
DO - 10.1080/00365540802078059
M3 - Article
C2 - 19086249
AN - SCOPUS:50549087896
SN - 0036-5548
VL - 40
SP - 761
EP - 765
JO - Scandinavian Journal of Infectious Diseases
JF - Scandinavian Journal of Infectious Diseases
IS - 9
ER -